Some patients with tenosynovial giant cell tumour (TGCT) might not be suitable for surgery for a number of reasons:1
complexity
and size1
contraindications2
fear of surgery3
might exacerbate
symptoms or cause
permanent joint damage4
Managing patients with TGCT who are not eligible for surgery can be challenging, especially in countries where the availability of alternative options may be limited.1,5
NON-SURGICAL ALTERNATIVES
The availability of non-surgical options for TGCT may differ, depending on the local availability of alternative treatments.1
Radiotherapy or cryotherapy
There is insufficient data to support the use of radiation or cryotherapy to treat TGCT1
Chemotherapy
Conventional chemotherapy is not indicated in TGCT1
SYSTEMIC TREATMENT
The systemic treatment landscape for TGCT is rapidly evolving, however the availability of these therapies may differ across countries1,5
TREATMENT FOR PATIENTS WITH ASYMPTOMATIC TGCT
Active surveillance (AS) is the preferred initial approach for asymptomatic TGCT. In some cases, it can also be considered for symptomatic patients at risk of major complications from treatment.1
However, long-term follow up on AS is limited, so the impact of AS on long-term joint health in TGCT is not known.5 If left untreated, TGCT may result in progressive joint deterioration.6
Click here to learn more about optimizing TGCT care through
multidisciplinary collaboration
